Neurologic complications of bone marrow transplantation

Handbook of Clinical Neurology

Volumn 121, Issue , 2014, Pages 1295-1304

  Rodriguez, Tulio E ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone marrow; Calcineurin inhibitors; Complications; Drugs; Encephalopathies; Infections; Neurologic; Stem cell; Total body irradiation; Transplantation

Indexed keywords

DRUG; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CALCINEURIN INHIBITORS; CHEMICALLY INDUCED DISORDER; COMPLICATIONS; ENCEPHALOPATHIES; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INFECTIONS; NEUROLOGIC; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PSYCHOLOGICAL ASPECT; STEM CELL; TRANSPLANTATION; WHOLE BODY RADIATION;

BONE MARROW; CALCINEURIN INHIBITORS; COMPLICATIONS; DRUGS; ENCEPHALOPATHIES; INFECTIONS; NEUROLOGIC; STEM CELL; TOTAL BODY IRRADIATION; TRANSPLANTATION;

BONE MARROW TRANSPLANTATION; BRAIN DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; NERVOUS SYSTEM DISEASES; POSTOPERATIVE COMPLICATIONS;

EID: 84890851385     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-7020-4088-7.00088-2     Document Type: Chapter

References (45)

1. Andersson B.S., Kashyap A., Gian V., et al. Conditioning therapy with intravenous busulfanand cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 2002, 8:145-154.
2. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
3. Barba P., Piñana J.L., Valcárcel D., et al. Early and late neurological complications after reduced intensity conditioning allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 2009, 15:1439-1446.
4. Bleggi-Torres L.F., de Medeiros B.C., Werner B., et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant. 2000, 25:301-307.
5. Bolton C.F., Young B. Managing the nervous system effects of sepsis. Chest 2007, 131:1273-1274.
6. Carson S.S., Kress J.P., Rodgers J.E., et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit. Care Med. 2006, 34:1326-1332.
7. CDC Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000, 49:1-125. CE 1-7.
8. Cohen J., Drage S. How I manage haematology patients with septic shock. Br. J. Haematol. 2011, 152:380-391.
9. de Brabander C., Cornelissen J., Smitt P.A., et al. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J. Neurol. Neurosurg. Psychiatry 2000, 68:36-40.
10. Dicke K.A., Zander A.R., Spitzer G., et al. Autologous bone marrow transplantation in relapsed adult acute leukemia. Exp. Hematol. 1979, 7(Suppl 5):170-187.
11. Dohgu S., Sumi N., Nishioku T., et al. Cyclosporin A induces hyperpermeability of the blood-brain barrier by inhibiting autocrine adrenomedullin-mediated up-regulation of endothelial barrier function. Eur. J. Pharmacol. 2010, 644:5-9.
12. Eberly A.L., Anderson G.D., Bubalo J.S., et al. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008, 28:1502-1510.
13. Garrick R. Neurological complications. Clinical Bone Marrow and Blood Stem Cell Transplantation 2000, 958-979. Cambridge University Press, Cambridge. K. Atkinson (Ed.).
14. Grauer O., Wolff D., Bertz H., et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease. Brain 2010, 133:2852-2865.
15. Hansen J.A., Clift R.A., Mickelson E.M., et al. Marrow transplantation from donors other than HLA identical siblings. Hum. Immunol. 1981, 2:31-40.
16. Henao N.A., Vagner B. Infections of the central nervous system by Candida. J Infect Dis Immun 2011, 3:79-84.
17. Iacobone E., Bailly-Salin J., Polito A., et al. Sepsis associated encephalopathy and its differential diagnosis. Crit. Care Med. 2009, 37(Suppl):S331-S336.
18. Jacobson L.O., Marks E.K., Robson M.J., et al. Effect of spleen protection on mortality following X-irradiation. J. Lab. Clin. Med. 1949, 34:1538-1543.
19. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit. Care Med. 2006, 34:1589-1596.
20. La Morgia C., Mondini S., Guarino M., et al. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol. Sci. 2004, 25:95-97.
21. Larson R.A., Geller R.B., Janisch L., et al. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial inpatients with advanced hematological malignancies. Cancer Chemother. Pharmacol. 1995, 36:204-210.
22. Laupacis A., Keown P.A., Ulan R.A., et al. Cyclosporin A: a powerful immunosuppressant. Can. Med. Assoc. J. 1982, 126:1041-1046.
23. Lee S.J., Flowers M.E. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program 2008, 2008:134-141.
24. Lin M.Y., Weinstein R.A., Hota B. Delay of active antimicrobial therapy and mortality among patients with bacteremia: impact of severe neutropenia. Antimicrob. Agents Chemother. 2008, 52:3188-3194.
25. Lindboe C.F., Loberg E.M. Wernicke's encephalopathy in nonalcoholics. An autopsy study. J. Neurol. Sci. 1989, 90:125-129.
26. Lorenz E., Uphoff D., Reid T.R., et al. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J. Natl. Cancer Inst. 1951, 12:197-201.
27. Majolino I., Caponetto A., Scimé R., et al. Wernicke-like encephalopathy after autologous bone marrow transplantation. Haematologica 1990, 75:282-284.
28. McCune J.S., Gibbs J.P., Slattery J.T. Plasma concentration monitoring of busulfan: does it improve clinical outcome?. Clin. Pharmacokinet. 2000, 39:155-165.
29. Openshaw H., Slatkin N.E. Hematopoietic Cell Transplantation 1999, 659-673. Blackwell Science, Malden, MA. 2nd edn. E.D. Thomas, K.G. Blume, S.J. Foreman (Eds.).
30. Papadopoulos M.C., Davies D.C., Moss R.F., et al. Pathophysiology of septic encephalopathy: a review. Crit. Care Med. 2000, 28:3019-3024.
31. Pasquini M.C., Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides Available at:. http://www.cibmtr.org.
32. Rubin J., Wide K., Remberger M., et al. Acute neurologicalcomplications after hematopoietic stem cell transplantation in children. Pediatr. Transplant. 2005, 9:62-67.
33. Sable C.A., Donowitz G.R. Infections in bone marrow transplant recipients. Clin. Infect. Dis. 1994, 18:273-281.
34. Siegal D., Keller A., Xu W., et al. Central nervous system complications after allogeneic hematopoietic stem cell transplantation: incidence, manifestations, and clinical significance. Biol. Blood Marrow Transplant. 2007, 13:1369-1379.
35. Speck B., Zwaan F.E., van Rood J.J., et al. Allogeneic bone marrow transplantation in a patient with aplastic anemia using a phenotypically HL-A-identical unrelated donor. Transplantation 1973, 16:24-28.
36. Takeshima K. Studies on bone marrow blood of atomic bomb victims who showed epilation. Acta Pathol. Jpn. 1953, 3:124-132.
37. Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977, 49:511-533.
38. Till J.E., McCulloch E.A. Early repair processes in marrow cells irradiated and proliferating in vivo. Radiat. Res. 1963, 18:96-105.
39. Uckan D., Cetin M., Yigitkanli I., et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005, 35:71-76.
40. Valcárcel D., Martino R., Sureda A., et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur. J. Haematol. 2005, 74:144-151.
41. van Rossum H.H., de Fijter J.W., van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther. Drug Monit. 2010, 32:3-10.
42. Vriesendorp H.M. Aims of conditioning. Exp. Hematol. 2003, 31:844-854.
43. Weber C., Schaper J., Tibussek D., et al. Diagnostic and therapeutic implications of neurological complications following paediatric haematopoietic stem cell transplantation. Bone Marrow Transplant. 2008, 41:253-259.
44. Yamashita M., Katsumata M., Iwashima M., et al. T cell receptor-induced calcineurin activation regulates T helper type 2 cell development by modifying the interleukin 4 receptor signaling complex. J. Exp. Med. 2000, 191:1869-1879.
45. Young G.B., Bolton C.F., Austin T.W., et al. The encephalopathy associated with septic illness. Clin. Invest. Med. 1990, 13:297-304.